Triple A Syndrome — consolidated literature audit
Scope and ontology anchor
Triple A syndrome (Allgrove syndrome) is anchored to MONDO:0009279 and to
biallelic loss-of-function variation in AAAS (hgnc:13666), encoding the
nuclear-pore protein ALADIN. The five duplicate PRs agreed on the disease
identity, inheritance, defining clinical triad, and proximal molecular lesion.
The final model treats it as a nucleoporin/neuroendocrine disorder rather than
an inborn error of intermediary metabolism.
Verified source set
Table (click to expand)
| Reference | Role in the final model |
|---|---|
| PMID:11062474 | AAAS discovery, defining triad, autonomic and neurological spectrum |
| PMID:12730363 | ALADIN nuclear-pore localization and mutant cytoplasmic mislocalization |
| PMID:16467144 | Selective nuclear import failure, impaired repair, oxidative-stress sensitivity |
| PMID:20687490 | Rarity, optic atrophy/amyotrophy, and organ-directed management |
| PMID:25554662 | Clinical hyperpigmentation |
| PMID:36194344 | Cohort evidence for dysautonomia and palmoplantar hyperkeratosis |
| PMID:42415167 | Contemporary case, biallelic AAAS confirmation, Schirmer testing, replacement therapy, myotomy/dilation |
The authoritative evidence inventory is the entry itself and its generated caches.
Reconciliation findings
Clinical completeness
The final phenotype set includes the classic triad of achalasia, alacrima, and ACTH-resistant primary adrenal insufficiency; dysphagia; central, peripheral, and autonomic neurological involvement; optic atrophy; amyotrophy; cutaneous hyperpigmentation; and palmoplantar keratoderma. Frequency is asserted only where a numeric cohort observation supports an ontology band.
Mechanism
The final pathograph preserves the best-supported causal sequence shared across
the drafts: pathogenic AAAS variation and ALADIN mistargeting at the nuclear
pore lead to selective nuclear-import failure, impaired delivery of DNA-repair
factors, oxidative-stress hypersensitivity, tissue-selective degeneration, and
adrenocortical failure. In-vitro molecular experiments remain tagged
IN_VITRO; patient manifestations and treatment observations remain
HUMAN_CLINICAL.
Diagnosis and management
The consolidated entry structures Schirmer testing and molecular confirmation instead of leaving diagnosis solely in prose. Management is separated into hydrocortisone and fludrocortisone replacement, Heller myotomy, endoscopic dilation, and artificial tears, with current NCIT procedure bindings and therapeutic agents where supported.
Prevalence discipline
The literature consistently calls the disorder rare but does not provide a
robust denominator-based worldwide estimate in the fetched sources. The final
entry therefore records a qualitative RARE class with measure_type:
UNKNOWN; it does not convert case counts or founder observations into an
unsupported numeric prevalence.
Excluded or deferred claims
- Antioxidants and N-acetylcysteine remain mechanistic or in-vitro leads, not established clinical therapies.
- No precise phenotype frequency is inferred from words such as “common.”
- No numeric worldwide prevalence rate is fabricated.
- Additional esophageal physiology tests may be curated when an exact, procedure-specific source is fetched.
Completeness conclusion
The five drafts were complementary: one had the strongest atomic mechanism, one the broadest phenotype coverage, and others supplied diagnosis, treatment, and review corrections. Their useful content is now represented once in the canonical YAML. Incremental histories, stale enum snapshots, and duplicate reference caches are not part of the consolidated change.